北京脑机接口交互技术位于全球头部行列

Core Insights - The "North Brain No. 1" GCP multi-center clinical trial is set to officially launch in October 2025, aiming for approval of Class III medical device certification within 2 to 3 years, significantly improving the quality of life for patients with severe conditions like paralysis [4][5] - Beijing is positioning itself as a leader in the brain-computer interface (BCI) sector, with a focus on rapid transformation from research to clinical application and industrialization, as part of its strategic layout for future industries [4][5] - The establishment of a 300 million yuan special fund to support enterprise incubation in the BCI field reflects the city's commitment to fostering innovation and technological advancement [4][6] Clinical Trials and Innovations - The "North Brain No. 1" device has already undergone preliminary clinical trials, with six successful human implantations reported, demonstrating significant improvements in motor and speech functions for patients with spinal cord injuries and strokes [5][6] - The clinical trial process is rigorous, involving patient recruitment, ethical approvals, and extensive pre- and post-operative training to ensure safety and efficacy [6] - The device utilizes a semi-invasive approach, which minimizes risks associated with traditional invasive methods while maintaining high signal quality [4][5] Industry Development and Support - Beijing's "AI + Brain Machine" strategy is part of a broader initiative to integrate advanced technologies into healthcare, with the goal of establishing a robust ecosystem for BCI innovation by 2030 [4][6] - The establishment of the Changping Brain Science and Brain-Computer Interface Industrial Park is a key component of this strategy, aiming to create a billion-level industrial cluster by 2030 [5][6] - The city has also introduced policies to support research and development in the BCI sector, including financial assistance for companies seeking medical device approvals [6]